L

Lineage Cell Therapeutics
D

LCTX

0.67590
USD
-0.02
(-2.40%)
مغلق
حجم التداول
1,035
الربح لكل سهم
-0
العائد الربحي
-
P/E
-7
حجم السوق
154,315,447
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADVM
    -0.03500
    (-0.88%)
    3.95000 USD
    L
    LGND
    -1.350
    (-1.11%)
    120.680 USD
    M
    MESO
    -0.798
    (-4.65%)
    16.350 USD
    P
    PSTV
    -0.09000
    (-6.98%)
    1.20000 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Lineage Cell Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.